BiotechTube
SK Pharmteco

SK Pharmteco

Lyon, France· Est.
skpharmteco.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

SK Pharmteco is a global CDMO formed in 2019, offering end-to-end manufacturing and development services for innovative therapies, including small molecules, peptides, and viral vectors for gene therapy. It positions itself as a strategic partner, emphasizing dedicated program management, seamless technology transfer, and proven regulatory expertise to accelerate client programs. The company targets the growing outsourcing needs of biopharma companies, aiming to reduce development risks and timelines for its clients.

Drug DeliverySmall MoleculesBiologics

Technology Platform

Integrated CDMO services platform for Small Molecule, Peptide, and Biologics/Cell & Gene Therapy (viral vector) manufacturing, supported by analytical development and regulatory services.

Opportunities

The company is well-positioned to capitalize on the booming demand for viral vector manufacturing for cell and gene therapies, a sector with constrained capacity.
Furthermore, the ongoing trend of biopharma outsourcing, especially among virtual and small biotechs, provides a steady stream of clients needing end-to-end development and manufacturing support.

Risk Factors

Key risks include operational execution risk (e.g., manufacturing failures, regulatory issues) at its facilities, which could severely damage client trust.
The company also faces intense competition in the crowded CDMO market and bears the risk of high capital expenditure requirements to stay technologically relevant, particularly in the fast-evolving CGT space.

Competitive Landscape

SK Pharmteco competes in a fragmented but competitive global CDMO market against large players like Lonza, Catalent, Thermo Fisher Scientific (Patheon), and Samsung Biologics, as well as numerous specialized firms. Its differentiation is based on a multi-modality offering (small molecule to gene therapy), a global facility footprint, and a stated emphasis on partnership and program management.

More companies in Small Molecule Drugs →More companies in France →